Hank Kimbrough, PhD

Element Materials Technology/Jones Microbiology Institute

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-1059) In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized ESBL and Carbapenemase positive Subsets Causing Urinary Tract Infections in the United States (2019-2022)
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1061) In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized Fluoroquinolone not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019-2022)
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1080) Aztreonam-Avibactam Activity Against Gram-negative Bacteria Isolated from Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023)
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1085) Characterization of Enterobacter cloacae and Citrobacter freundii Species Ccomplex Isolates with Decreased Susceptibility to Cephalosporins from United States Hospitals and Activity of Aztreonam-avibactam and Comparator Agents (2019-2023).
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1100) Activity of Cefiderocol and Comparator Agents Against Global Isolates of Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2023)
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1361) Cefiderocol Activity against Pseudomonas aeruginosa, Including Resistant Subsets and Isolates Carrying Carbapenemase β-lactamase Genes, from United States Hospitals (2020–2023)
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1362) Cefiderocol Activity against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2023)
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1363) Cefiderocol Activity against Clinical Enterobacterales Isolates Carrying Metallo-β-lactamase Genes in United States and European Hospitals (2020–2023)
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1364) Cefiderocol Activity against Pseudomonas aeruginosa Clinical Isolates Carrying Metallo-β-lactamase Genes in United States and European Hospitals (2020–2023)
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1526) In vitro Activity of Ceftobiprole Against Prominent Methicillin-resistant Staphylococcus aureus Clonal Groups Collected Through the SENTRY Antimicrobial Surveillance Program
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1527) Update on the Activity of Ceftobiprole against Gram-positive Clinical Bacterial Isolates Causing Skin and Skin-structure Infections in the United States (2016–2020).
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT